KalVista Pharmaceuticals’ (KALV) Buy Rating Reaffirmed at Jones Trading
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Jones Trading ...
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Rating of “Buy” from Analysts
Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) have earned an average recommendation of “Buy” from ...
KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of ...
TD Cowen Reaffirms Their Buy Rating on KalVista Pharmaceuticals (KALV)
TD Cowen analyst Stacy Ku maintained a Buy rating on KalVista Pharmaceuticals (KALV – Research Report) today and set a price target of $30.00.
Stifel Nicolaus Keeps Their Buy Rating on KalVista Pharmaceuticals (KALV)
Detailed price information for Kalvista Pharmaceuticals Inc (KALV-Q) from The Globe and Mail including charting and trades.
KalVista completes enrollment in KONFIDENT-KID clinical trial of sebetralstat
Pharmaceuticals announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an ...
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...
Healio11d
On-demand sebetralstat effective for hereditary angioedema attacks in larynx
Patients with hereditary angioedema whose attacks impacted their larynx experienced on-demand relief within 1.29 hours with ...
Yahoo Finance16d
KalVista Pharmaceuticals, Inc. (KALV)
Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.
ADVFN17d
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase ...
Finanznachrichten18d
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den ...